Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viagenpumatucel-L + Cyclophosphamide vs Chemotherapy in Advanced NSCLC
NCT02117024Phase 2Terminated
- Sponsor
- NightHawk Biosciences, Inc.
- Start
- Jul 2014
- Primary completion
- Dec 2017
- Modality
- Prophylactic Vaccines, Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of viagenpumatucel-L in non-small cell lung cancer (NSCLC), sponsored by NightHawk Biosciences, Inc. Primary endpoint: Overall Survival at 3 years. Started Jul 2014; status: terminated.
02
Drugs
viagenpumatucel-L
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02117024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117024.